Trial · NCT03099382

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

NCT03099382, Phase 3, Completed, Jiangsu HengRui Medicine Co., Ltd.; results first posted 2024-01-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer. Trials, record NCT03099382. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03099382

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
NCT number: NCT03099382
Status: Completed
Phases: Phase 3
Enrollment: 457 participants, actual
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Conditions: Esophageal Carcinoma
Interventions: camrelizumab, Docetaxel, Irinotecan
First posted: 2017-04-04
Last updated: 2024-01-22
Results first posted: 2024-01-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Survival (OS)	approximately 24 months

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Survival (OS)	approximately 24 months		months	MEDIAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall Survival (OS)	Camrelizumab		8.28	95% Confidence Interval 6.77 to 9.72	months
Overall Survival (OS)	Investigator's Choice of Standard Therapy		6.24	95% Confidence Interval 5.68 to 6.93	months

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Camrelizumab	228
Overall Study	STARTED	Investigator's Choice of Standard Therapy	220
Overall Study	COMPLETED	Camrelizumab	226
Overall Study	COMPLETED	Investigator's Choice of Standard Therapy	217
Overall Study	NOT COMPLETED	Camrelizumab	2
Overall Study	NOT COMPLETED	Investigator's Choice of Standard Therapy	3

Source ClinicalTrials.gov

Adverse events272

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	Camrelizumab	102	228
other	Anaemia	Blood and lymphatic system disorders	Investigator's Choice of Standard Therapy	107	220
other	Sinus tachycardia	Cardiac disorders	Camrelizumab	13	228
other	Sinus tachycardia	Cardiac disorders	Investigator's Choice of Standard Therapy	6	220
other	Hypothyroidism	Endocrine disorders	Camrelizumab	40	228
other	Hypothyroidism	Endocrine disorders	Investigator's Choice of Standard Therapy	11	220
other	Hyperthyroidism	Endocrine disorders	Camrelizumab	14	228
other	Hyperthyroidism	Endocrine disorders	Investigator's Choice of Standard Therapy	2	220
other	Constipation	Gastrointestinal disorders	Camrelizumab	39	228
other	Constipation	Gastrointestinal disorders	Investigator's Choice of Standard Therapy	26	220

1 to 10 of 272Source ClinicalTrials.gov

See all 272 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Camrelizumab	23	228
Total, all-cause mortality	Investigator's Choice of Standard Therapy	10	220
Total, other adverse events	Camrelizumab	226	228
Total, other adverse events	Investigator's Choice of Standard Therapy	210	220
Total, serious adverse events	Camrelizumab	71	228
Total, serious adverse events	Investigator's Choice of Standard Therapy	52	220

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
32416073	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Camrelizumab vs Investigator's Choice of Standard Therapy: deaths from any cause	Trial comparisons
Camrelizumab vs Investigator's Choice of Standard Therapy: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03099382

GET https://conductscience.org/api/trials/v1/NCT03099382/events?page=2

API reference For AI assistants